论文部分内容阅读
目的:探讨灯盏花素温度敏感型鼻用原位凝胶对改善脑缺血的药效作用,为开发灯盏花素鼻用原位凝胶给药系统提供参考依据。方法:将SD大鼠随机分为假手术组、模型组、灯盏细辛静脉注射组、灯盏花素温敏凝胶鼻腔给药高低剂量组、灯盏花素鼻腔给药微球组。在线栓法制备大鼠局灶型脑缺血模型(MCAO)的基础上,进行大鼠神经行为学评分及TTC染色检测大鼠脑梗死面积,评价灯盏花素温度敏感型鼻用原位凝胶对脑缺血保护的药效作用。结果:灯盏花素鼻用原位凝胶高剂量组及其低剂量组的行为学评分与模型组均有显著性差异(P<0.05),与灯盏花素注射液组和微球组比较无显著性差异(P>0.05);鼻腔给药高、低剂量组大鼠的平均脑梗死面积比为7.81%、14.24%,与模型组(20.69%)、静脉注射组(10.81%)和微球组(10.69%)比较均具有统计学意义(P<0.05)。结论:研究表明灯盏花素鼻用温敏凝胶对脑缺血确有改善作用,且优于静脉注射。
Objective: To investigate the efficacy of breviscapine temperature-sensitive nasal in situ gel for improving cerebral ischemia, and provide a reference for the development of Breviscapine nasal in situ gel delivery system. Methods: SD rats were randomly divided into sham operation group, model group, Xanthium sinensis injection group, breviscapine thermo-sensitive gel intranasally administered high dose group, Breviscapine nasal administration group. On the basis of preparation of rat focal cerebral ischemia model (MCAO) by online suture method, the neurobehavioral score and TTC staining were used to detect the area of cerebral infarction in rats. The breviscapine temperature-sensitive nasal in situ gel Protective effect on cerebral ischemia. Results: The scores of behavior of breviscapine nasal in situ gel high dose group and its low dose group were significantly different from that of the model group (P <0.05), compared with the breviscapine injection group and the microsphere group (P> 0.05). The average cerebral infarction area ratio in high and low dose nasal administration groups was 7.81% and 14.24%, which was significantly higher than that in model group (20.69%), intravenous injection group (10.81%) and microsphere Group (10.69%) were statistically significant (P <0.05). Conclusion: The study shows that Breviscapine nasal thermosensitive gel has a good effect on cerebral ischemia, and is superior to intravenous injection.